ZZFIRST

OFFICIAL TITLE: A BIOMARKER–DISCOVERY PHASE II TRIAL OF ENZALUTAMIDE AND TALAZOPARIB (PF-06944076) FOR THE TREATMENT OF METASTATIC HORMONE–NAÏVE PROSTATE CANCER. MEDOPP234 – ZZFIRST (EUDRACT# 2019-003096-20)

PROJECT DETAILS

ZZFIRST IS A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO-ARM, PHASE II CLINICAL TRIAL IN MEN WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC). 

THE PRIMARY GOAL IS TO EVALUATE THE ANTITUMOR ACTIVITY OF TALAZOPARIB (PF-06944076) IN COMBINATION WITH ENZALUTAMIDE AND ADT -AS DETERMINED BY THE CONFIRMED PROSTATE-SPECIFIC ANTIGEN-COMPLETE RESPONSE (PSA-CR)- IN PATIENTS WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC).

ZZFIRST AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

(mHNPC)

II

54

9

Spain

Start up

ZZFIRST SITES

SPAIN

Hospital Universitari Vall D'Hebrón

SPAIN

Hospital Clínic i Provincial de Barcelona

SPAIN

Hospital Universitario 12 de Octubre

SPAIN

Institut Català d'Oncologia Badalona (ICO)

SPAIN

Hospital del Mar

SPAIN

Hospital Universitario Miguel Servet

SPAIN

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Provincial de Castellón

SPAIN

Hospital Universitario Virgen de la Victoria